Visit for the latest Coronavirus Disease (COVID-19) updates.

You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 

Fibrates for Primary Prevention of Cardiovascular Disease Events

Description of Resource: 
Cardiovascular disease is the most common cause of death, illness, disability, and reduced quality of life in industrialized countries. Fibrates are a class of drugs that work by positively influencing fats in the blood. This systematic review sought to evaluate the benefits and harms of using fibrate treatment compared to placebo or usual care for preventing cardiovascular disease in people at increased risk of developing cardiovascular disease. This review identified 6 trials and found a risk reduction of 16% with fibrate therapy for the combined outcome of death due to cardiovascular disease, heart attack, or stroke.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
Cochrane Review
Developer Type: 
Non-Federal Government
Healthy People 2020 Topic Area(s): 
Heart Disease and Stroke
Healthy People 2020 Objectives: 
Resource Type: 
Systematic Review
Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev [Internet]. 2016 [cited 2017 Dec 29];(11). Art. No.: CD009753. doi: 10.1002/14651858.CD009753.pub2. Available from: